3. THE BRAND LOGO
(It’s Transformation through the time)
•Butterfly represents “LIFE at its energetic best”
•Molecule in between represents “ Pharmaceutical bent of the
Company”
•Flight of the butterfly represents “soaring aspirations of the
company” and
• BLUE color represents “ Health, Healing, Wisdom and
Confidence.
4. ABOUT THE COMPANY
•A Public Ltd. Company
•Founded in 1949 by K.B. Mehta and N.S. Tibrawala in Mumbai (INDIA)
•Headquarters situated at Mumbai
•Current Management Team: Mr. Prem Chandra Godha (Managing Director)
Mr. A.K.Jain (Joint Managing Director)
•Areas served is worldwide
•Products Manufactured: Pharmaceuticals and Drugs
•Business Model: Fully integrated Pharmaceutical company mfg. branded and generic
formulations, active pharmaceutical ingredients and intermediates
5. •Total income in the F.Y. 2012-13: Rs. 2797.08 Crores
•Total exports in F.Y. 2012-13: Rs.1716.08 Crores
•Manufacturing Facilities:
Pithampur (Madhya Pradesh)
Athal (Gujrat)
Dehradun (Uttarakhand)
Kandla (Gujrat)
Ratlam (Madhya Pradesh)
Indore (Madhya Pradesh)
Ankaleshwar (Gujrat)
Mahad (Maharashtra)
•International Presence: U.S.A., U.K., Australia, New Zealand, Nigeria and China
•Marketing Offices (Abroad): Kenya, Philippines, Vietnam, Columbia, Peru, Malaysia, Sri
Lanka
•Major Subsidiaries: CCPL Soft wares(For Patient Counseling)
PADAAV (IPCA Traditional Remedy Center for Ayurvedic Treatment)
•At one time the control of the company was held by THE BACHCHANS in 1975
8. MARKETTING DIVISIONS OF THE
COMPANY
Deals with Cardio-diabetic disorders
Deals with cardio diabetic disorders and lipid
management
Deals with rheumatologic and orthopedic disorders
Deals with surgical and non surgical equipments
Deals with dermatological disorders
Deals with first line treatment of patients
10. MAJOR COMPETITORS IN THE MARKET
MERCK INDUSTRIES LTD.
NATCO PHARMACEUTICALS LTD.
UNICHEM LABORATORIES LTD.
PLETHICO
PHARMACEUTICALS LTD.
11. MARKET STRATEGY OF THE COMPANY
•Major focus on high value products and reduction in dependence on low value
generic products.
•Entry of the company in the U.S. markets through tie ups with RANBAXY and
HARIATGE Pharma
•Aggressive ANDA (Abbreviated New Drug Application) in the U.S. Markets.
•Maintaining Therapy focused marketing divisions.
•In house clinical research facilities and focusing on the safety and well being of
the of the patient.
•Exports in over 120 countries across the globe and marketing offices in every major
continent.
•Continuous introduction of new products in domestic and international markets.
13. STRENGTHS
WEAKNESS
•Worldwide presence in anti malarial
market capturing almost 1/3rd of the
market.
•Focus on brand building and
promotional activities is less.
•Large network of wholesalers and
sales and marketing executives.
•Strong and stable financial position of
the company.
•Dosage forms against all malarial
disorders.
•Major attention on formulation
segment.
•Presence in international market.
•Limited and slow market share
growth.
14. OPPORTUNITIES
THREATS
•Increasing demand for
therapeutic drugs in the Indian
and Chinese market.
•Reduced funds and infrastructure
facilities for public healthcare
•Acquisition of more and more
research based firms will help
increase the therapeutic product
range to a great extent.
•Expansion in the therapeutic
segment in Nutraceutical,
nephrology and urology will
improve profits.
•Depreciating value of currency poses
a threat to the research driven
activities
•Global economic slowdown
16. CORPORATE SOCIAL RESPONSIBILITIES OF THE
COMPANY
Health
Education
and
Awareness
Employees and
Society
Development
CSR ACTIVITIESAREAS OF OPERATION
Health and
Safety
Environment
Management
Systems